Prot #MK-3682-012-01: A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection.

Project: Research project

Project Details

StatusFinished
Effective start/end date8/5/15 → 8/5/18

Funding

  • Merck Sharp & Dohme Corporation (MK-3682-012-01)